Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$9.19
-11.7%
$9.53
$2.31
$13.70
$32.29M-0.66117,813 shs96,749 shs
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$14.44
-1.0%
$13.53
$9.83
$17.75
$135.61M0.918,286 shs17,848 shs
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
$0.98
-20.7%
$0.98
$0.71
$4.60
$129.09M-0.041.29 million shs3.46 million shs
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$5.00
-1.2%
$3.49
$1.97
$22.47
$149.65M1.2300,986 shs139,376 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-11.72%-4.87%+19.35%-18.53%+59.71%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
-0.96%+3.14%+0.98%-4.33%-3.73%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-20.67%+1.30%+11.06%-16.60%-76.66%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-1.19%-2.72%+48.81%+4.82%-77.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.5529 of 5 stars
0.03.00.00.02.71.70.0
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
4.4844 of 5 stars
3.75.00.00.02.53.33.1
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
4.2902 of 5 stars
3.24.00.04.22.61.71.3
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
3.6952 of 5 stars
4.44.00.00.03.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
2.00
HoldN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
3.33
Buy$20.5041.97% Upside
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
2.33
Hold$3.00207.44% Upside
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83576.67% Upside

Current Analyst Ratings Breakdown

Latest COEP, SLN, FTLF, and RAPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00
5/22/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$6.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
3/17/2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
3/10/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/7/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
3/5/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.00
3/4/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.00
3/4/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$6.00 ➝ $4.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$62.87K513.63N/AN/A$0.48 per share19.15
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$63.86M2.12$0.76 per share19.05$3.04 per share4.75
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
$1.53M84.37N/AN/A$4.27 per share0.23
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$27.70M5.40N/AN/A$0.71 per share7.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$21.27M-$5.80N/AN/AN/A-1,094.50%-219.97%N/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$5.30M$0.8417.0913.13N/A13.38%28.03%15.13%N/A
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/14/2025 (Estimated)
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/A

Latest COEP, SLN, FTLF, and RAPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.24$0.20-$0.04$0.20N/AN/A
5/14/2025Q1 2025
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/A-$1.11N/A-$1.11N/AN/A
5/8/2025Q1 2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$0.31-$0.08+$0.23-$0.08N/AN/A
5/8/2025Q1 2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
3/27/2025Q4 2024
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.22$0.21-$0.01N/AN/AN/A
3/6/2025Q4 2024
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$0.45-$1.14-$0.69-$1.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
N/AN/AN/AN/AN/A
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
N/AN/AN/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.03
0.40
0.40
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
0.28
1.50
0.64
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
N/A
9.90
9.90
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/A
9.31
9.31

Institutional Ownership

CompanyInstitutional Ownership
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
13.88%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
2.32%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
99.09%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
24.25%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
61.30%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
2.36%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
23.51 million2.46 millionNot Optionable
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
209.39 million3.56 millionNot Optionable
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
80132.29 million32.65 millionOptionable
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
10029.93 millionN/ANot Optionable

Recent News About These Companies

Silence Therapeutics plc GAAP EPS of -C$0.20

New MarketBeat Followers Over Time

Media Sentiment Over Time

Coeptis Therapeutics stock logo

Coeptis Therapeutics NASDAQ:COEP

$9.19 -1.22 (-11.72%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.60 +0.41 (+4.41%)
As of 05/27/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

FitLife Brands stock logo

FitLife Brands NASDAQ:FTLF

$14.42 -0.17 (-1.13%)
As of 05/27/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

RAPT Therapeutics stock logo

RAPT Therapeutics NASDAQ:RAPT

$0.98 -0.25 (-20.67%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.98 +0.00 (+0.43%)
As of 05/27/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.00 -0.06 (-1.19%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.02 +0.02 (+0.40%)
As of 05/27/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.